Merck’s Capital Idea: Pharma’s Latest Attempt to Get Closer to VCs
Executive Summary
Competition for biotech’s most eligible assets has never been stronger. As such, some pharmas are trying harder than ever to get in on the ground floor.
You may also be interested in...
Merck Adds Flagship To Its Venture Fund Network
Merck contributes to Flagship’s latest fund, both sides promise to share ideas and expertise, but Merck gets no special rights to companies or products in Flagship’s portfolio.
Pharma Plus: Merck’s Global Health Innovation Fund
Realizing that future winners in the health care world will be those companies with broad-based and comprehensive health care offerings, Merck & Co. Inc. tasked a group of executives with identifying and pursuing investment opportunities in what it calls health care adjacencies.
Lilly's Evolving Corporate Venture Model
Of all the big pharmaceutical companies, Eli Lilly & Co. has arguably been the most aggressive and creative in finding outsiders to help develop their drugs. With its latest venture, Lilly hopes to learn lessons from a past failed initiative. The Indianapolis drug firm is set to put up to $150 million to work, backing three traditional venture funds as part of a strategy that outsources development of its own molecules.